Lewes, DE -- (SBWIRE) -- 07/25/2016 -- Multiple Sclerosis pipeline therapeutics constitutes close to 323 molecules. Out of which approximately 279 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report Multiple Sclerosis – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Multiple Sclerosis Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 12, 29, 31, 166, 36 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 38 and 2 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. Driven by data built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis

- The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Multiple Sclerosis therapeutics and enlists all their major and minor projects

- The report assesses Multiple Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For more information Visit at: http://www.marketresearchreports.com/global-markets-direct/multiple-sclerosis-pipeline-review-h1-2016

Related Reports:

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016; visit at - http://www.marketresearchreports.com/global-markets-direct/c-c-chemokine-receptor-type-5-c-c-ckr-5-or-chemr13-or-hiv-1-fusion-coreceptor

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin-8 Receptor B or IL-8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H1 2016; visit at - http://www.marketresearchreports.com/global-markets-direct/c-x-c-chemokine-receptor-type-2-cdw128b-or-gromgsa-receptor-or-high-affinity

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions